Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Felbamate is a carbamate structurally related to meprobamate. It is used in the treatment of epilepsy (refractory partial seizures with or without secondary generalization and in children with Lennox-Gastaut syndrome. Due to its toxicity, it should only be used in severe cases that do not respond to other drugs. Oral administration in 3 to 4 daily doses.
At the date of the last update we found no published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low binding to plasma proteins and prolonged half-life) make it likely to pass into breast milk in quantities that could be significant.
Due to its possible serious side effects: aplastic anemia, hepatic failure, Stevens-Johnson syndrome… (Jacob 2016), this drug is not recommended during lactation, preferring other known safer drugs. (Veiby 2015, Bar-Oz 2000, Hägg 2000)